Epigenetic approaches in the treatment of myelodysplastic syndromes: clinical utility of azacitidine

References

• WarlickEDSmithBDMyelodysplastic syndromes: review of pathophysiology and current novel treatment approachesCurr Cancer Drug Targets20077654155817896920
   PubMed Web of Science ®Google Scholar
• HermanJGCivinCIIssaJPDistinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignanciesCancer Res19975758378419041182
   PubMed Web of Science ®Google Scholar
• LeoneGTeofiliLVosoMTLubbertMDNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemiasHaematologica200287121324134112495905
   PubMed Web of Science ®Google Scholar
• QuesnelBGuillermGVereecqueRMethylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progressionBlood1998918298529909531610
   PubMed Web of Science ®Google Scholar
• AggerholmAHolmMSGuldbergPOlesenLHHoklandPPromoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patientsEur J Haematol2006761233216343268
   PubMed Web of Science ®Google Scholar
• ChristiansenDHAndersenMKPedersen-BjergaardJMethylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemiaLeukemia20031791813181912970781
   PubMed Web of Science ®Google Scholar
• KantarjianHIssaJPRosenfeldCSDecitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized studyCancer200610681794180316532500
   PubMed Web of Science ®Google Scholar
• KantarjianHOkiYGarcia-ManeroGResults of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemiaBlood20071091525716882708
   PubMed Web of Science ®Google Scholar
• SilvermanLRDemakosEPPetersonBLRandomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group BJ Clin Oncol200220102429244012011120
   PubMed Web of Science ®Google Scholar
• SilvermanLRMcKenzieDRPetersonBLFurther analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group BJ Clin Oncol200624243895390316921040
   PubMed Web of Science ®Google Scholar
• FenauxPMuftiGJHellstrom-LindbergEEfficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III studyLancet Oncol200910322323219230772
   PubMed Web of Science ®Google Scholar
• KaminskasEFarrellAAbrahamSApproval summary: azacitidine for treatment of myelodysplastic syndrome subtypesClin Cancer Res200511103604360815897554
   PubMed Web of Science ®Google Scholar
• StresemannCLykoFModes of action of the DNA methyltransferase inhibitors azacytidine and decitabineInt J Cancer2008123181318425818
   PubMed Web of Science ®Google Scholar
• IssaJPKantarjianHMTargeting DNA methylationClin Cancer Res200915123938394619509174
   PubMed Web of Science ®Google Scholar
• GriffithsEAGoreSDDNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromesSemin Hematol2008451233018179966
   PubMed Web of Science ®Google Scholar
• FandyTECarrawayHGoreSDDNA demethylating agents and histone deacetylase inhibitors in hematologic malignanciesCancer J2007131404817464245
   PubMed Web of Science ®Google Scholar
• SchermellehLSpadaFEaswaranHPTrapped in action: direct visualization of DNA methyltransferase activity in living cellsNat Methods200521075175616179921
   PubMed Web of Science ®Google Scholar
• FandyTEHermanJGKernsPEarly epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignanciesBlood2009114132764277319546476
   PubMed Web of Science ®Google Scholar
• GoreSDIn vitro basis for treatment with hypomethylating agents and histone deacetylase inhibitors: can epigenetic changes be used to monitor treatment?Leuk Res200933Suppl 2S2S620004793
   PubMed Web of Science ®Google Scholar
• ShenLKantarjianHGuoYDNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromesJ Clin Oncol201028460561320038729
   PubMed Web of Science ®Google Scholar
• KaronMSiegerLLeimbrockS5-Azacytidine: a new active agent for the treatment of acute leukemiaBlood19734233593654125239
   PubMed Web of Science ®Google Scholar
• McCredieKBBodeyGPBurgessMATreatment of acute leukemia with 5-azacytidine (NSC-102816)Cancer Chemother Rep19735733193234127393
   PubMedGoogle Scholar
• ShniderBIBaigMColskyJA phase I study of 5-azacytidine (NSC-102816)J Clin Pharmacol197616420521257124
   PubMed Web of Science ®Google Scholar
• VoglerWRMillerDSKellerJW5-Azacytidine (NSC 102816): a new drug for the treatment of myeloblastic leukemiaBlood197648333133760156
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050794s011lbl.pdf. Accessed Feb 1, 2010.
   Google Scholar
• LyonsRMCosgriffTMModiSSHematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromesJ Clin Oncol200927111850185619255328
   PubMed Web of Science ®Google Scholar
• MacBethKJLailleENingYA comparative pharmacokinetic/pharmacodynamic (PK/PD) evaluation of azacitidine following subcutaneous (SC) and oral administration in subjects with myelodysplastic syndromes (MDS) or acute myelogenous leukemia (AML), results from a phase 1 studyASH Annu Meet Abstr2009114221772
   Google Scholar
• Garcia-ManeroGGoreSDSkikneBA phase 1, open-label, dose-escalation study to evaluate the safety, pharmacokinetics, and pharmacodynamics of oral azacitidine in patients with myelodysplastic syndromes (MDS) or acute myelogenous leukemia (AML)ASH Annu Meet Abstr200911422117
   Google Scholar
• TroetelWMWeissAJStambaughJELauciusJFMantheiRWAbsorption, distribution, and excretion of 5-azacytidine (NSC-102816) in manCancer Chemother Rep197256340541119051502
   PubMedGoogle Scholar
• KaminskasEFarrellATWangYCSridharaRPazdurRFDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspensionOncologist200510317618215793220
   PubMed Web of Science ®Google Scholar
• ChabotGGRivardGEMomparlerRLPlasma and cerebrospinal fluid pharmacokinetics of 5-Aza-2′-deoxycytidine in rabbits and dogsCancer Res19834325925976184151
   PubMed Web of Science ®Google Scholar
• SilvermanLRHollandJFWeinbergRSEffects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromesLeukemia19937Suppl 1S21S29
   PubMed Web of Science ®Google Scholar
• ChesonBDBennettJMKantarjianHReport of an international working group to standardize response criteria for myelodysplastic syndromesBlood200096123671367411090046
   PubMed Web of Science ®Google Scholar
• KornblithABHerndonJEIISilvermanLRImpact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B studyJ Clin Oncol200220102441245212011121
   PubMed Web of Science ®Google Scholar
• GurionRVidalLGafter-GviliA5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome – a systematic review and meta-analysisHaematologica201095230331019773261
   PubMed Web of Science ®Google Scholar
• MaslakPChanelSCamachoLHPilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndromeLeukemia200620221221716357841
   PubMed Web of Science ®Google Scholar
• BraitehFSorianoAOGarcia-ManeroGPhase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancersClin Cancer Res200814196296630118829512
   PubMed Web of Science ®Google Scholar
• SorianoAOYangHFaderlSSafety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndromeBlood200711072302230817596541
   PubMed Web of Science ®Google Scholar
• NandSGodwinJSmithSHydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trialLeuk Lymphoma200849112141214719021057
   PubMed Web of Science ®Google Scholar
• KenealyMKSeymourJFLindaCThe tolerability of combination therapy with thalidomide and 5-azacitidine in patients with advanced myelodysplastic syndromes (MDS)ASH Annu Meet Abstr2009114221749
   Google Scholar
• SekeresMAListAFCuthbertsonDPhase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromesJ Clin Oncol201028132253225820354132
   PubMed Web of Science ®Google Scholar
• De Padua SilvaLde LimaMKantarjianHFeasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndromeBone Marrow Transplant2009431183984319151791
   PubMed Web of Science ®Google Scholar
• FieldTPerkinsJHuangY5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantationBone Marrow Transplant201045225526019543327
   PubMed Web of Science ®Google Scholar
• Sanchez-AbarcaLIGutierrez-CosioSSantamariaCImmunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation settingBlood2010115110712119887673
   PubMed Web of Science ®Google Scholar
• PlatzbeckerUAulCEhningerGGiagounidisAReduction of 5-azacitidine induced skin reactions in MDS patients with evening primrose oilAnn Hematol201089442742819714330
   PubMed Web of Science ®Google Scholar
• PinchonDJStanworthSJDoreeCBrunskillSNorfolkDRQuality of life and use of red cell transfusion in patients with myelodysplastic syndromes. A systematic reviewAm J Hematol2009841067167719705430
   PubMed Web of Science ®Google Scholar
• CaocciGBaccoliRLeddaALitteraRLa NasaGA mathematical model for the evaluation of amplitude of hemoglobin fluctuations in elderly anemic patients affected by myelodysplastic syndromes: correlation with quality of life and fatigueLeuk Res200731224925216814382
   PubMed Web of Science ®Google Scholar
• OlivaENDimitrovBDBenedettoFD’AngeloANobileFHemoglobin level threshold for cardiac remodeling and quality of life in myelodysplastic syndromeLeuk Res200529101217121916111537
   PubMed Web of Science ®Google Scholar
• StasiRAbruzzeseELanzettaGTerzoliEAmadoriSDarbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromesAnn Oncol200516121921192716166176
   PubMed Web of Science ®Google Scholar
• BalleariERossiEClavioMErythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre studyAnn Hematol200685317418016408206
   PubMed Web of Science ®Google Scholar
• CasadevallNDurieuxPDuboisSHealth, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trialBlood2004104232132715054036
   PubMed Web of Science ®Google Scholar
• GabriloveJPaquetteRLyonsRMPhase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromesBr J Haematol2008142337939318540943
   PubMed Web of Science ®Google Scholar
• SteensmaDPHeptinstallKVJohnsonVMCommon troublesome symptoms and their impact on quality of life in patients with myelodysplastic syndromes (MDS): results of a large internet-based surveyLeuk Res200832569169818054795
   PubMed Web of Science ®Google Scholar
• BorthakurGAhdabSERavandiFActivity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidineLeuk Lymphoma200849469069518398735
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Available from: http://www.clinicaltrials.gov. Accessed May 9, 2010.
   Google Scholar
• FaderlSVerstovsekSCortesJClofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or olderBlood20061081455116403905
   PubMed Web of Science ®Google Scholar
• FaderlSGandhiVO’BrienSResults of a phase 1–2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemiasBlood2005105394094715486072
   PubMed Web of Science ®Google Scholar
• FaderlSGarcia-ManeroGEstrovZOral clofarabine in the treatment of patients with higher-risk myelodysplastic syndromeJ Clin Oncol201028162755276020421540
   PubMed Web of Science ®Google Scholar
• ScottBLRamakrishnanAFosdalMAnti-thymocyte globulin plus etanercept as therapy for myelodysplastic syndromes (MDS): a phase II studyBr J Haematol2010149570671020331464
   PubMed Web of Science ®Google Scholar
• MusolinoCSant’antonioEPennaGEpigenetic therapy in myelodysplastic syndromesEur J Haematol201084646346720192987
   PubMed Web of Science ®Google Scholar
• FenauxPAdesLReview of azacitidine trials in intermediate-2-and high-risk myelodysplastic syndromesLeuk Res200933Suppl 2S7S1120004796
   PubMed Web of Science ®Google Scholar